Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Research facility
Location:
Mexico City,
Mexico (MX)
ISNI: 0000000106984037
ROR: https://ror.org/00xgvev73
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis (2022)
Efe C, Tascilar K, Gerussi A, Bolis F, Lammert C, Ebik B, Stättermayer AF, et al.
Journal article
Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys (2022)
Naveen R, Joshi M, Sen P, Agarwal V, Shinjo S, Kardes S, Lilleker JB, et al.
Conference contribution
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial (2022)
Waijer SW, Vart P, Cherney DZ, Chertow GM, Jongs N, Langkilde AM, Mann JFE, et al.
Journal article
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis (2021)
Efe C, Lammert C, Tascilar K, Dhanasekaran R, Ebik B, Higuera-De La Tijera F, Caliskan AR, et al.
Journal article
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease (2021)
McMurray JJ, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, et al.
Journal article
Dapagliflozin in Patients with Chronic Kidney Disease (2020)
Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann J, et al.
Journal article
Epidemiology, molecular, and genetic methodologies to evaluate causes of CKDu around the world: report of the Working Group from the ISN International Consortium of Collaborators on CKDu (2019)
Anand S, Caplin B, Gonzalez-Quiroz M, Schensul SL, Bhalla V, Parada X, Nanayakkara N, et al.
Journal article, Editorial